Propanc Biopharma (PPCB) Q3 2026 earnings summary

Executive summary

• Advanced lead product PRP to a pivotal Phase 1b clinical study for advanced cancer patients, with ongoing preclinical work and recent patent filings for synthetic and stabilized formulations.

• Entered multi-year research collaborations with Spanish universities to expand anti-aging and cancer research and support new patent applications.

• No revenue generated; operations centered on R&D, patent protection, and preparation for clinical trials.

• Significant decrease in net loss year-over-year due to lower stock-based compensation and consulting expenses.

• Secured a private placement agreement for up to $100 million, with $2 million received by March 31, 2026, to accelerate clinical development.

Financial highlights

• Net loss for Q3 2026 was $6.36M, down from $54.07M in Q3 2025; nine-month net loss was $14.29M, down from $54.85M year-over-year.

• No revenue reported for the periods; operating expenses for the quarter were $6.4M, mainly from administration and R&D.

• Cash at March 31, 2026 was $443,702, up from $12,088 at June 30, 2025.

• Total assets at March 31, 2026 were $14.33M; total liabilities decreased by $2.10M to $3.51M.

• Convertible notes reduced significantly to $55,000 from $538,000 year-over-year.

Outlook and guidance

• Management highlights substantial doubt about the ability to continue as a going concern due to recurring losses, negative working capital, and reliance on external financing.

• Ongoing efforts to secure additional funding through equity and debt offerings; failure to obtain financing may curtail operations.

• Financing facility expected to support ongoing R&D, including advancement of PRP and Rec-PRP.

• Preparation underway for regulatory submission of the clinical trial application later in 2026.